This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Pasquino, A. M. Articles by Segni, M. Search for Related Content PubMed PubMed Citation Articles by Pasquino, A. M. Articles by Segni, M.

Adult Height in Short Normal Girls Treated with Gonadotropin-Releasing Hormone Analogs and Growth Hormone

Pediatric Endocrinology Unit, Pediatric Radiology Unit (M.R.), Pediatric Department, University La Sapienza, 00161 Rome, Italy

Address all correspondence and requests for reprints to: Anna Maria Pasquino, M.D., Pediatric Endocrinology Unit, Pediatric Department, University La Sapienza, Viale Regina Elena 324, 00161 Rome, Italy.

Combined treatment with GH and GnRH analogs (GnRHa) has been proposed to improve final adult height in true precocious puberty, GH deficiency, and short normal subjects with early or normal timing of puberty with still controversial results. We treated 12 girls with idiopathic short stature and normal or early puberty with GH and GnRHa and followed them to adult height; 12 girls comparable for auxological and laboratory characteristics treated with GH alone served to better evaluate the efficacy of addition of GnRHa. At the start of combined treatment, the chronological age of the girls (CA; mean ± SD) was 10.2 ± 0.9 yr, bone age (BA) was 10.6 ± 1.9 yr, height SD score for BA was -1.81 ± 0.8, PAH was 146.3 ± 5.0 cm. PAH was significantly lower than target height (TH 152.7 ± 3.6 cm; P < 0.005). GH was given at a dose of 0.3 mg/kg·week, sc, 6 days weekly, and GnRHa (depot-triptorelin) was given at a dose of 100 µg/kg every 21 days, im. The 12 girls were treated with GH alone at the same dose; at the start of therapy their CA was 10.7 ± 1.0, BA was 10.1 ± 1.4 yr, height SD score for BA was -1.65 ± 0.8, PAH was 145.6 ± 4.4 cm, and TH was 155.8 ± 4.6 cm. Pubertal Tanner stage in both groups was B2P2 or B3P3. LHRH test and pelvic ultrasound showed the beginning of puberty. The GH response to standard provocative tests was 10 g/L or more. The mean period of treatment was 4.6 ± 1.7 yr in the group treated with GH plus GnRHa and 4.9 ± 1.4 yr in the group treated with GH alone; both groups discontinued treatment at comparable CA and BA. Adult height was considered to be attained when growth during the preceding year was less than 1 cm, with a BA of over 15 yr. Patients in the group treated with GH plus GnRHa showed an adult height significantly higher (P < 0.001) than the pretreatment PAH (156.3 ± 5.9 vs. 146.3 ± 5 cm); the gain in centimeters calculated between pretreatment PAH and adult height was 10 ± 2.9 cm, and 7 of 12 girls had a gain over 10 cm. Target height was significantly exceeded. Height SD score for BA increased from -1.81 ± 0.8 to -0.85 ± 1.0. The GH alone group reached an adult height higher than the pretreatment PAH (151.7 ± 2.7 vs. 145.6 ± 4.4 cm); the gain in final height vs. pretreatment PAH was 6.1 ± 4.4 cm, and 5 of 12 girls did not gain more than 4 cm. TH was even not reached. The height SD score did not significantly change. No adverse effects were observed in either group. All of the girls showed good compliance and were satisfied with the results. Our experience suggests that the combination of GH and GnRHa is significantly more effective in improving adult height than GH alone in girls with idiopathic short stature, early or normal onset of puberty, and low PAH well below the third percentile and TH. As the cost-benefit of such invasive treatment must be seriously considered, further studies are needed due to the small sample of our patients as well as in other studies reported to date.

This article has been cited by other articles:

				D. I. Shulman, G. L. Francis, M. R. Palmert, E. A. Eugster, and for the Lawson Wilkins Pediatric Endocrine Society Use of Aromatase Inhibitors in Children and Adolescents With Disorders of Growth and Adolescent Development Pediatrics, April 1, 2008; 121(4): e975 - e983. [Abstract] [Full Text] [PDF]

				N. Mauras, L. Gonzalez de Pijem, H. Y. Hsiang, P. Desrosiers, R. Rapaport, I. D. Schwartz, K. O. Klein, R. J. Singh, A. Miyamoto, and K. Bishop Anastrozole Increases Predicted Adult Height of Short Adolescent Males Treated with Growth Hormone: A Randomized, Placebo-Controlled, Multicenter Trial for One to Three Years J. Clin. Endocrinol. Metab., March 1, 2008; 93(3): 823 - 831. [Abstract] [Full Text] [PDF]

				S. A. van Gool, G. A. Kamp, H. Visser-van Balen, D. Mul, J. J. J. Waelkens, M. Jansen, L. Verhoeven-Wind, H. A. Delemarre-van de Waal, S. M. P. F. de Muinck Keizer-Schrama, G. Leusink, et al. Final Height Outcome after Three Years of Growth Hormone and Gonadotropin-Releasing Hormone Agonist Treatment in Short Adolescents with Relatively Early Puberty J. Clin. Endocrinol. Metab., April 1, 2007; 92(4): 1402 - 1408. [Abstract] [Full Text] [PDF]

				J.-C. Carel, P. Chatelain, P. Rochiccioli, and J.-L. Chaussain Improvement in Adult Height after Growth Hormone Treatment in Adolescents with Short Stature Born Small for Gestational Age: Results of a Randomized Controlled Study J. Clin. Endocrinol. Metab., April 1, 2003; 88(4): 1587 - 1593. [Abstract] [Full Text] [PDF]

				J. A. Yanovski, S. R. Rose, G. Municchi, O. H. Pescovitz, S. C. Hill, F. G. Cassorla, and G. B. Cutler Jr. Treatment with a Luteinizing Hormone-Releasing Hormone Agonist in Adolescents with Short Stature N. Engl. J. Med., March 6, 2003; 348(10): 908 - 917. [Abstract] [Full Text] [PDF]

				M. Maniati-Christidi, S. Livadas, A. Voutetakis, G. Tolis, and C. Dacou-Voutetakis Human Growth Hormone and Gonadotropin Releasing Hormone Analog Combination Therapy Increases Predicted Height in Short Normal Girls Clinical Pediatrics, January 1, 2003; 42(1): 59 - 65. [Abstract] [PDF]

				B. S. Finkelstein, T. F. Imperiale, T. Speroff, U. Marrero, D. J. Radcliffe, and L. Cuttler Effect of Growth Hormone Therapy on Height in Children With Idiopathic Short Stature: A Meta-analysis Arch Pediatr Adolesc Med, March 1, 2002; 156(3): 230 - 240. [Abstract] [Full Text] [PDF]

				D. Mul, J .M. Wit, W. Oostdijk, and J. Van den Broeck The Effect of Pubertal Delay by GnRH Agonist in GH-Deficient Children on Final Height J. Clin. Endocrinol. Metab., October 1, 2001; 86(10): 4655 - 4656. [Full Text] [PDF]

				P. B. Kaplowitz If Gonadotropin-Releasing Hormone Plus Growth Hormone (GH) Really Improves Growth Outcomes in Short Non-GH-Deficient Children, Then What? J. Clin. Endocrinol. Metab., July 1, 2001; 86(7): 2965 - 2968. [Full Text] [PDF]

				G. A. Kamp, D. Mul, J. J. J. Waelkens, M. Jansen, H. A. Delemarre-van de Waal, L. Verhoeven-Wind, M. Frolich, W. Oostdijk, and J. M. Wit A Randomized Controlled Trial of Three Years Growth Hormone and Gonadotropin-Releasing Hormone Agonist Treatment in Children with Idiopathic Short Stature and Intrauterine Growth Retardation J. Clin. Endocrinol. Metab., July 1, 2001; 86(7): 2969 - 2975. [Abstract] [Full Text] [PDF]

				R. Lanes and P. Gunczler Final Adult Height in Short Healthy Children Treated with Growth Hormone and Gonadotropin-Releasing Hormone Analogs J. Clin. Endocrinol. Metab., January 1, 2001; 86(1): 458 - 458. [Full Text]